Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. / Ali, Abir Salwa; Grönberg, Malin; Federspiel, Birgitte; Scoazec, Jean Yves; Hjortland, Geir Olav; Grønbæk, Henning; Ladekarl, Morten; Langer, Seppo W.; Welin, Staffan; Vestermark, Lene Weber; Arola, Johanna; Österlund, Pia; Knigge, Ulrich; Sorbye, Halfdan; Grimelius, Lars; Janson, Eva Tiensuu.
I: PLOS ONE, Bind 12, Nr. 11, e0187667, 11.2017.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
AU - Ali, Abir Salwa
AU - Grönberg, Malin
AU - Federspiel, Birgitte
AU - Scoazec, Jean Yves
AU - Hjortland, Geir Olav
AU - Grønbæk, Henning
AU - Ladekarl, Morten
AU - Langer, Seppo W.
AU - Welin, Staffan
AU - Vestermark, Lene Weber
AU - Arola, Johanna
AU - Österlund, Pia
AU - Knigge, Ulrich
AU - Sorbye, Halfdan
AU - Grimelius, Lars
AU - Janson, Eva Tiensuu
PY - 2017/11
Y1 - 2017/11
N2 - Background Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, rapidly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short lasting. The aim of this study was to examine the expression and potential clinical importance of immunoreactive p53 protein in GEP-NEC. Materials and methods Tumor tissues from 124 GEP-NEC patients with locally advanced or metastatic disease treated with platinum-based chemotherapy were collected from Nordic centers and clinical data were obtained from the Nordic NEC register. Tumor proliferation rate and differentiation were re-evaluated. All specimens were immunostained for p53 protein using a commercially available monoclonal antibody. Kaplan-Meier curves and cox regression analyses were used to assess progression-free survival (PFS) and overall survival (OS). Results All tumor tissues were immunoreactive for either one or both neuroendocrine biomarkers (chromogranin A and synaptophysin) and Ki67 index was >20% in all cases. p53 immunoreactivity was only shown in 39% of the cases and was not found to be a prognostic marker for the whole cohort. However, p53 immunoreactivity was correlated with shorter PFS in patients with colorectal tumors (HR = 2.1, p = 0.03) in a univariate analysis as well as to poorer PFS (HR = 2.6, p = 0.03) and OS (HR = 3.4, p = 0.02) in patients with colorectal tumors with distant metastases, a correlation which remained significant in the multivariate analyses. Conclusion In this cohort of GEP-NEC patients, p53 expression could not be correlated with clinical outcome. However, in patients with colorectal NECs, p53 expression was correlated with shorter PFS and OS. Further studies are needed to establish the role of immunoreactive p53 as a prognostic marker for GEP-NEC patients.
AB - Background Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, rapidly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short lasting. The aim of this study was to examine the expression and potential clinical importance of immunoreactive p53 protein in GEP-NEC. Materials and methods Tumor tissues from 124 GEP-NEC patients with locally advanced or metastatic disease treated with platinum-based chemotherapy were collected from Nordic centers and clinical data were obtained from the Nordic NEC register. Tumor proliferation rate and differentiation were re-evaluated. All specimens were immunostained for p53 protein using a commercially available monoclonal antibody. Kaplan-Meier curves and cox regression analyses were used to assess progression-free survival (PFS) and overall survival (OS). Results All tumor tissues were immunoreactive for either one or both neuroendocrine biomarkers (chromogranin A and synaptophysin) and Ki67 index was >20% in all cases. p53 immunoreactivity was only shown in 39% of the cases and was not found to be a prognostic marker for the whole cohort. However, p53 immunoreactivity was correlated with shorter PFS in patients with colorectal tumors (HR = 2.1, p = 0.03) in a univariate analysis as well as to poorer PFS (HR = 2.6, p = 0.03) and OS (HR = 3.4, p = 0.02) in patients with colorectal tumors with distant metastases, a correlation which remained significant in the multivariate analyses. Conclusion In this cohort of GEP-NEC patients, p53 expression could not be correlated with clinical outcome. However, in patients with colorectal NECs, p53 expression was correlated with shorter PFS and OS. Further studies are needed to establish the role of immunoreactive p53 as a prognostic marker for GEP-NEC patients.
U2 - 10.1371/journal.pone.0187667
DO - 10.1371/journal.pone.0187667
M3 - Journal article
C2 - 29112960
AN - SCOPUS:85033222567
VL - 12
JO - PLoS ONE
JF - PLoS ONE
SN - 1932-6203
IS - 11
M1 - e0187667
ER -
ID: 189090837